B10 | HEPTA-REFRACTORY MULTIPLE MYELOMA: BIOLOGY, PROGNOSIS, AND TREATMENT
Introduction. Despite major therapeutic advances, including T-cell–engaging therapies, most patients with multiple myeloma (MM) eventually relapse. An increasing number of patients are presenting with disease refractory to CD38-targeting antibodies, two immunomodulatory drugs (IMiDs), two proteasom...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Ferrata Storti Foundation
2026-04-01
|
| Saila: | Haematologica |
| Sarrera elektronikoa: | https://haematologica.org/article/view/14087 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
